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Abstract
Background:  Treatment options for patients with recurrent superficial bladder cancer are
limited, necessitating aggressive exploration of new treatment strategies that effectively prevent
recurrence and progression to invasive disease. We assessed the effects of belinostat (previously
PXD101), a novel histone deacetylase inhibitor, on a panel of human bladder cancer cell lines
representing superficial and invasive disease, and on a transgenic mouse model of superficial bladder
cancer.
Methods: Growth inhibition and cell cycle distribution effect of belinostat on 5637, T24, J82, and
RT4 urothelial lines were assessed. Ha-ras transgenic mice with established superficial bladder
cancer were randomized to receive either belinostat or vehicle alone, and assessed for bladder
weight, hematuria, gene expression profiling, and immunohistochemistry (IHC).
Results: Belinostat had a significant linear dose-dependent growth inhibition on all cell lines (IC50
range of 1.0–10.0 µM). The 5637 cell line, which was derived from a superficial papillary tumor, was
the most sensitive to treatment. Belinostat (100 mg/kg, intraperitoneal, 5 days each week for 3
weeks) treated mice had less bladder weight (p < 0.05), and no hematuria compared with 6/10
control mice that developed at least one episode. IHC of bladder tumors showed less cell
proliferation and a higher expression of p21WAF1 in the belinostat-treated mice. Gene expression
profile analysis revealed 56 genes significantly different in the treated group; these included the
upregulation of p21WAF1, induction of core histone deacetylase (HDAC), and cell communication
genes.
Conclusion: Our data demonstrate that belinostat inhibits bladder cancer and supports the
clinical evaluation of belinostat for the treatment of patients with superficial bladder cancer.
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Background
Bladder cancer is a major health care problem in the
United States and accounts for approximately 13,000
deaths annually [1]. The majority of bladder tumors are
initially diagnosed as superficial, however, 70% of
patients experience recurrence, and 30% progress to inva-
sive disease [2]. This high rate of recurrence requires
patients to undergo lifelong follow-up exams, prophylac-
tic treatments, and additional surgical resection. This pro-
tracted natural prevalence of bladder cancer is estimated
to affect approximately 500,000 people, and the manage-
ment of this disease exceeds $4 billion in healthcare
expenditures annually [2,3]. It is critically important to
aggressively explore pharmacological treatment strategies
that can effectively prevent superficial bladder cancer
recurrence and progression to invasive disease.
Histone deacetylase inhibitors (HDACIs) represent a new
mechanistic class of anti-cancer therapeutics that target
HDAC enzymes and have been shown to: arrest growth of
cancer cells (including drug resistant subtypes), induce
apoptosis, promote differentiation, inhibit angiogenesis,
and sensitize cancer cells to overcome drug resistance
when used in combination with other anti-cancer agents.
Although many HDACIs have been shown to enhance
histone acetylation and to increase the expression of
tumor suppressor genes in cancerous cells, the exact
mechanism(s) that HDACIs effectively inhibit cancer cell
growth remains an area of active investigation, and may
involve the acetylation of both histone and nonhistone
proteins.
HDACIs represent a promising new class of antineoplastic
agents for the treatment of bladder cancer. A Phase I clin-
ical trial of suberoylanilide hydroxamic acid (SAHA)
showed that 2 out of 4 bladder cancer patients responded
to treatment with objective tumor regression and clinical
improvement [4]. A new hydroxamate type HDACI
known as belinostat was chosen for this study because in
vitro experiments showed that it had a potent anti-tumor
effect at sub- to low micromolar IC50 potency in several
tumor cell lines [5-8]. Phase I clinical studies have also
suggested that belinostat and other HDACIs have anti-
tumor effects [9-12], and that belinostat can specifically
inhibit tumor growth in animal models at non-toxic con-
centrations [5,6,8]. We have examined the effects of
PXD101 on bladder tumor cell growth and proliferation,
both in vitro and in vivo.
Because the majority of bladder cancer is initially diag-
nosed as superficial and frequently progresses to invasive
disease, we chose to use an expanded panel of human
transitional cell carcinoma (TCC) cell lines to include
superficial variants in addition to the more commonly
used highly invasive disease variants.
The lack of a functionally relevant model system for in
vivo testing of potential agents has also limited bladder
cancer research and therapy development. Currently, anti-
cancer agents are screened in vivo using human xenograft
tumor models grown subcutaneously in athymic mice
before initiation of a clinical trial. In many cases,
xenografts are selected to suit the putative mechanism of
the agent tested, the approach being one of proof of prin-
cipal in an in vivo model, rather than testing the new
agent in a clinically relevant and predictive model. Our
group has developed a transgenic mouse model of blad-
der tumorigenesis using a urothelium-specific promoter
to drive the urothelial expression of specific activated
tumor oncogenes [13-15]. One of these models expressed,
in a urothelium-specific manner, a constitutively active
Ha-ras, known to be a frequent event in about 30–40% of
human bladder cancers [16,17]. Homozygous mice har-
boring two alleles of the Ha-ras mutant consistently devel-
oped low-grade, non-invasive, superficial papillary
bladder tumors. These transgenic mice have been charac-
terized in detail and were chosen for our in vivo studies.
[14-16,18,19]. Ha-ras mice reproducibly develop superfi-
cial bladder cancer by 3 months of age and continue to
form low-grade superficial papillary tumors that rapidly
increase in size in the following 3 months. These mice
eventually succumb to obstructive neuropathy at 6–7
months. This reproducible and predictable time course of
tumor onset and development lent itself as a well-defined
model for screening belinostat and other potential chem-
otherapeutic agents to test their abilities to hinder the
development and progression of superficial bladder can-
cer.
Herein, we show that belinostat treatment inhibited cell
growth and proliferation in a dose-dependent fashion and
caused cell cycle arrest in our panel of urinary bladder can-
cer cell lines. We also show that treatment of Ha-ras trans-
genic bladder cancer mice with belinostat decreased
bladder tumor growth with no apparent toxicity and
induced p21WAF1 and other HDAC core and cell commu-
nication genes. These findings suggest that belinostat may
represent a novel adjuvant treatment for patients with
superficial recurrent bladder cancer.
Methods
Cell culture, proliferation assay and belinostat
The human urinary bladder carcinoma cell lines 5637,
T24, J82 and RT4 were obtained from the American Type
Culture Collection (Manassas, VA). All tumor cell lines
were maintained in DMEM (Sigma; St Louis, MO), sup-
plemented with 10% FBS, and maintained at 37°C with
5% CO2. Cells were seeded into 96-well tissue culture
plates (J82 at 2000 cells/well; 5637, T24 and RT4 at 4000
cells/well), allowed to attach and grow for 24 h, exposed
to 1–10 µM of belinostat for 48 h, and cell proliferationJournal of Translational Medicine 2007, 5:49 http://www.translational-medicine.com/content/5/1/49
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was assessed using the WST-1 tetrazolium salt cleavage
assay kit (Chemicon; Temecula, CA) as per the manufac-
turer's instructions.
Belinostat has been previously described [6] and was pre-
pared as a 10 mM stock in DMSO/PBS for in vitro studies.
For animal studies, belinostat was dissolved in L-Arginine
to give a final concentration of 20 mg/ml. This formula-
tion gave sufficient solubility for doses of ≤ 40 mg/kg.
Belinostat was kindly provided by CuraGen Corp.,
TopoTarget and the National Cancer Institute.
Cell cycle analysis
FACS analysis was performed on cells treated with 5 µM
belinostat for 48 h, harvested with trypsin-EDTA (Sigma;
St Louis, MO), and fixed in absolute ethanol overnight at
-20°C. Immediately before analysis, cells were treated
with 200 ug/mL DNAse-free RNAseA (Sigma; St Louis,
MO) for 30 minutes at 37°C, then treated with 1 mg/mL
propidium iodide (Sigma; St Louis, MO). Cells were ana-
lyzed using a FACScan (Becton Dickinson; Franklin Lakes,
NJ) at an excitation wavelength of 488 nm at the NYU
Cancer Institute's Flow Cytometry and Cell Sorting Core
Facility.
Generation of UPII-Ha-ras transgenic mice and belinostat 
treatment
The transgenic model used for this study specifically
expressed a constitutively activated Ha-ras oncogene in
the urothelium under the control of a 30-kb mouse uro-
plakin II promoter [15]. Intercrossing of heterozygous
mice yielded homozygous offspring that consistently and
reproducibly developed superficial bladder cancers at
well-defined time points [19,20]. Homozygous mice were
distinguished from heterozygotes by Southern blotting of
tail genomic DNA. DNA was digested with NcoI, resolved
by gel electrophoresis, and hybridized with a 32P-labeled,
UPII probe (600-base pairs), which allowed detection of
both the endogenous UPII gene and the mUPII/Ha-ras-M
transgene. Densitometric analysis of the genomic South-
ern blot was used to calculate the relative amount of trans-
gene present by comparing transgene with endogenous
UPII gene. Breeding and housing of mice were conducted
at the Manhattan VA Medical Center under the guidance
of Tung-Tien Sun and Xue-Ru Wu. Animal Studies were
carried out at the Manhattan VA Medical Center under
IACUC guidelines of the New York Harbor Healthcare
System and conformed to their guidelines for the welfare
of animals in experimental neoplasia. The starting point
of belinostat was set at 3 months of age when all
homozygous mice were known to have established blad-
der tumors. Twenty Ha-ras mice were randomized into
two groups of 10 per group. Ten mice received intraperi-
toneal (IP) injections containing belinostat dissolved in L-
Arginine each day for 5 days each week for 3 weeks (100
mg/kg, IP, 5 days each week for 3 weeks), and 10 received
IP injections with L-Arginine alone following the same
dose scheduling. Mice were weighed twice weekly,
checked daily for gross hematuria by applying light pres-
sure on the bladder, and monitored for any changes in
behavior or condition. One day after the last dosing
(when mice were 3 months and 22 days old) all twenty
mice were sacrificed, bladders were removed, weighed
after voiding of all urine, necroscopied, divided for RNA
isolation, and paraffin embedded for IHC.
Histopathology of mouse bladder tumors
All bladders and tumors were analyzed histopathologi-
cally and all were confirmed to be superficial with no evi-
dence of invasion. We also looked for differences in
necrosis, mitotic figures, and the extent of tumor burden
present in all bladders.
Microarray Analysis
All mouse bladders were processed for total RNA isolation
and all subsequent technical procedures including purity
and concentration of RNA, cDNA synthesis, biotin labe-
ling of cRNA, and hybridization and scanning of arrays
were performed by Genome Explorations, Inc. (Memphis,
TN). Briefly, RNA integrity was determined by capillary
electrophoresis using the RNA 6000 Nano Lab-on-a-Chip
kit and the Bioanalyzer 2100 (Agilent Technologies). In
order to obtain sufficient highly pure RNA for gene profil-
ing it was essential to identify and pool the best quality
RNA from three animal bladders per treatment group (15
µg). Our transgenic mice represented a homogeneous bio-
logic entity. Similarly, other investigators using the same
GeneChips have pooled RNA from transgenic mice organs
for subsequent microarray analysis [21,22]. Preparation
of the cRNA and the subsequent microarray processes
were performed as described in the Affymetrix GeneChip
expression analysis technical manual (Affymetrix; Santa
Clara, CA). Briefly, cRNA was hybridized to Affymetrix
MOE 430 2.0 short oligomer arrays, which detect approx-
imately 45,000 mouse transcripts representing over
34,000 well-characterized mouse genes. The results were
analyzed using programs resident in GeneChip Operating
System v1.4 (GCOS; Affymetrix). Conversion of gene
names or accession numbers to Affymetrix probe set IDs
was accomplished using NetAffx. Probe sets were identi-
fied by pair-wise comparison in GCOS using a 2-fold
change threshold, and the GCOS-generated Change calls
and Detection calls were used in our filtering criteria to
identify robust expression changes. Signal intensity heat
map figures were generated using http://www.gen
esifter.net. Due to an inadequate amount of bladder tis-
sue, gene analysis was performed on pooled RNA samples
with no replicates. Our gene analysis was an investiga-
tional type of array given that a traditional p-value couldJournal of Translational Medicine 2007, 5:49 http://www.translational-medicine.com/content/5/1/49
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not be generated due to the lack of sufficient individual
RNA samples.
Immunohistochemistry of mouse bladder tumors
Freshly dissected bladder tissues were fixed in 10% buff-
ered formalin and processed routinely for paraffin embed-
ding. Three-micron tissue sections were stained with
hemotoxylin/eosin and examined microscopically. To
determine the proliferative and apoptotic capacity of the
tumors, we stained sections for the expression of prolifer-
ation specific antigen (Ki-67) using the mouse mono-
clonal antibody MIB1 (Immunotech SA; France), and
assessed the expression of p21WAF1 using MAb clone 2G12
(PharMingen; San Diego, CA), both as described previ-
ously [23].
Image quantitation of Ki67 and p21WAF1 IHC staining
The quantitative digital analysis of the IHC stained slides
for Ki67 and p21WAF1 involved the following modifica-
tions from methodology previously developed [24,25]
using Kodak Molecular Imaging (MI) software (Ver 4.0,
New Haven, CT): all slides were reviewed by a pathologist
who captured a representative area using Olympus Digital
Vision v3.0 (Center Valley, PA) at 20× objective magnifi-
cation and output as a TIFF file. The image was imported
into Adobe Photoshop CS2 (Adobe Systems Inc.; San Jose
CA) and the image color was standardized across all
images using the auto level function. In Photoshop, the
wand function was then used to subtract immunonegative
portions of the image. Tumor images excluded areas con-
taining preparation artifact and any necrotic or benign
regions. The final image was imported into Kodak MI
where automatic conversion to grayscale occurred fol-
lowed by utilization of the "automatic region-of-interest"
function for the entire image. The density slice mode was
used with the threshold visually adjusted (over the setting
of 0–255) to select for only immunopositive staining
tumor pixels. The pixel size was unrestricted, and the auto-
matic find function was set to search for immunopositive
pixels using smooth edges. The interior area of the posi-
tively staining pixel regions-of-interest was determined by
the Kodak MI analysis, and the sum was calculated using
Microsoft Excel. To obtain percent staining, the sum of the
interior area of the positively staining pixels was divided
by the entire interior pixel area for the image being ana-
lyzed. To obtain fold change in staining for p21WAF1 in the
belinostat-treated mice over the arginine-treated group,
the percent staining of the belinostat group was divided
by the percent staining of the arginine treatment group. To
obtain fold change in staining for Ki67 in the arginine
treated mice over the belinostat-treated group, the percent
staining of the arginine group was divided by the percent
staining of the belinostat treated group.
Statistical Analysis
Cell proliferation and FACS analysis experiments were
performed at least three times independently, with 3–8
repeats at each data point. Statistical analysis was per-
formed using GraphPad Instat version 3.0 (Graph Pad
Software Inc.; San Diego, CA). Statistical significance was
calculated using the Students two-tailed t test, where p <
0.05 was considered significant.
Results
Belinostat inhibited bladder cancer cell growth
The in vitro treatment of all four urothelial carcinoma cell
lines at 1–5 µM belinostat for 48 h caused a dose-depend-
ent inhibition of proliferation, with the most potent
inhibitory effect occurring on 5637 cells (IC50 of 1.0 µM),
and the least effect occurring on RT4 cells (IC50 of 10.0
µM). T24 and J82 cell lines had an IC50 of 3.5 and 6.0
µM, respectively. Treatment with 5 µM belinostat for 48 h
caused a 71% (± 0.2, SEM) decrease in cell growth and
proliferation for 5637 cells, 51% (± 1.0) for T24, 41% (±
2.0) for J82, and 23% (± 7.9) for RT4 cells (Figure 1). All
cell lines, except the RT4 line, showed a significant growth
inhibition (GI) when compared to control at all concen-
trations of belinostat (1, 2 and 5 µM) (p < 0.001). RT4
Inhibition of bladder cancer cell proliferation by belinostat at  1, 2 and 5 µM for 48 h in the human urinary bladder cancer  cell lines 5637, T24, J82 and RT4 Figure 1
Inhibition of bladder cancer cell proliferation by belinostat at 
1, 2 and 5 µM for 48 h in the human urinary bladder cancer 
cell lines 5637, T24, J82 and RT4. Percent inhibition from 
control was determined using the WST-1 tetrazolium salt 
cleavage assay. Bars are representative of at least 3 independ-
ent experiments and are the mean of at least 8 wells per con-
dition. Error bars indicate SEM.
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cells only showed a significant GI at 5 µM belinostat when
compared to control (p = 0.01).
Induction of cell cycle arrest by belinostat
Cell cycle analysis showed that, 48 h after the 5637 blad-
der carcinoma cells were treated with 5 µM belinostat,
there was an 18% (± 1.0, SD) increase of cells in the G0-
G1 phase, and a 16% (± 1.0) decrease in S phase (Figure
2); indicating the cells were arrested at the G0-
G1transition. The J82 cells showed a moderate 10% (±
0.7) decrease in S phase cells. RT4 cells showed minor
changes in cell cycle parameters: 6% (± 0.8) build up of
cells in G0-G1, and 5% (± 0.4) decrease in S phase.
Belinostat reduced mice bladder weights, decreased 
hematuria and was well-tolerated
The transgenic mice used in this study all had established
superficial bladder cancer when treatment was initiated,
therefore this study was one that explored the effect of
belinostat on established superficial bladder cancer, and
not one that sought to prevent initiation. The bladder epi-
thelium of our Ras-expressing transgenic mice undergo
tumorigenic changes resulting in a 300% increase in blad-
der weight at 3 months of age (30 mg Ha-ras bladder ver-
sus 10 mg normal non-transgenic mouse bladder).
Consistent with previous studies in non-transgenic mice
[26], the increase in male bladder weight due to tumor
formation occurred at a faster rate than in females. Belino-
stat caused a 50% (p = 0.03; Figure 3a) and 36% (p = 0.04;
Figure 3b) decrease in the weights of Ras-expressing blad-
ders of the male and female transgenic mice, respectively.
Effect of belinostat on cell cycle distribution in 5637 cells Figure 2
Effect of belinostat on cell cycle distribution in 5637 cells. 5637 cells were the most sensitive to belinostat treatment and 
showed the greatest accumulation of G0-G1 cells, decrease in S phase cells and increase in G2-M phase cells after treatment. 
Cells cultured with 5 µM belinostat for 48 h were analyzed by flow cytometry, and percent cell cycle distribution was assessed 
by standard histogram analysis.
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While untreated Ras-expressing transgenic mice showed
many episodes of hematuria (male mice 2/4: one mouse
with one episode on day 3, and one mouse with one epi-
sode on day 7 and day 16; female mice 4/6: two mice with
one episode on day 7, and two mice with one episode on
day 16), none of the belinostat-treated mice had hematu-
ria (male mice 0/4, female mice 0/5). The lack of any inci-
dence of hematuria demonstrated that all mice being
treated with belinostat experienced decreased progression
of bladder disease compared to vehicle alone. Haematuria
in this model might be considered a sign of bladder can-
cer. Although development of haematuria is not in com-
plete parallel with the development of bladder cancer,
haematuria has been consistently reported as the most
common symptom of bladder cancer in humans [27]. The
comparison of the rate of haematuria in the control arm
versus that in the belinostat treated arm was consistent
with our suggestion that haematuria in our mouse model
mirrors, at least in part, the human counterpart. In addi-
tion, belinostat showed no detectable toxicity as evaluated
by weight (male and female belinostat-treated mice
showed a 1% (p = 0.19) and 11% (p = 0.70) increase in
body weight, respectively. Pathological examination at
necroscopy also showed no significant abnormalities
(including necrosis or mitotic figures) between the two
groups. Bladder tumors in the treated mice were smaller
and occupied less space of the total bladder capacity.
There were no striking histopathological differences
between the two treatment groups, however IHC of Ki67
showed an increase in cell proliferation in the control
mice over that of belinostat-treated mice (Figure 4a). IHC
analysis also showed an increase of p21WAF1 expression in
the belinostat-treated mice over that of the control (Figure
4b).
Belinostat induced p21WAF1, HDAC core and cell 
communication genes
cDNA microarray studies of mouse bladder tumors
revealed 22 HDAC core genes that were significantly up-
or downregulated due to belinostat treatment (Table 1).
These genes are involved in cell cycle regulation, apopto-
sis and DNA synthesis. The most prominently upregu-
lated genes due to belinostat treatment were
metallothionein 1, hepatoma derived growth factor, CTP
synthase, fucosidase, and p21WAF1. The most dominantly
downregulated genes were clusterin, histone H2be, and
tubulin alpha 4. We also determined that 34 cell commu-
nication genes were differentially expressed due to belino-
stat treatment (Table 2).
Belinostat decreases both male and female bladder weights in transgenic superficial bladder cancer mice Figure 3
Belinostat decreases both male and female bladder weights in transgenic superficial bladder cancer mice. Ha-ras transgenic 
mice with established superficial bladder cancer were randomized to receive either belinostat dissolved in L-Arginine (100 mg/
kg, IP, qd, 5 days on, 2 days off, 3 cycles) or L-Arginine alone as a control following the same dose scheduling. All bladders were 
voided of urine prior to weighing. Normal non-transgenic mouse bladders weigh approximately 10.0 mg at the same age, and 
Ha-ras transgenic mice with superficial bladder cancer have a 3 fold and higher bladder weight. A, Male belinostat-treated mice 
(n = 4, 327.5 mg average weight) showed a two-fold decrease (50%, p = 0.03) in bladder weight versus control (n = 4, 652.5 mg 
average weight). B, Female belinostat-treated mice (n = 5, 34.0 mg average weight) showed a 36% decrease (p = 0.04) in blad-
der weight versus control (n = 6, 53.3 mg average weight).
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Discussion
This is the first study to demonstrate the low micromolar
potency of belinostat in human bladder cancer cells.
Although we did not conduct a comparative study and test
any other HDACIs alongside belinostat, we feel that a
non-direct comparison to other HDACs is important. Our
data demonstrated that in comparison with other HDA-
CIs such as valproic acid and sodium butyrate, belinostat
had greater potency, required only 3.5 µM to achieve an
IC50 in T24 cells, and also had a relatively lower micromo-
lar IC50 range of 1.0–10.0 µM for the 5637, J82 and RT4
cell lines (IC50 data for J82 and RT4 not shown). Other
HDACIs, such as valproic acid, have required millimolar
concentrations in order to achieve an IC50 in the T24 cell
line [28-30]. This high concentration of valproic acid
resulted in the dose-limiting neurotoxicity observed in the
clinical setting [28]. Other groups have had better success
using 10–20 µM SAHA to achieve an IC50 on T24 cells
[31]. Belinostat had a similar effect on cell cycle distribu-
tion compared with other HDACIs such as trichostatin A
(TSA), sodium butyrate, and SAHA [29,32,33]. All of
these agents have been reported to decrease S-phase and
IHC staining of transgenic mice bladders for A, the cell proliferation marker Ki67 and B, P21 in L-Arginine treated (left panel)  and belinostat-treated bladder cancer mice (right panel) Figure 4
IHC staining of transgenic mice bladders for A, the cell proliferation marker Ki67 and B, P21 in L-Arginine treated (left panel) 
and belinostat-treated bladder cancer mice (right panel). Images are representative of 9 belinostat-treated mice and 10 control 
treated with vehicle alone (L-Arginine) selected by a pathologist. All images at 20× objective magnification.Journal of Translational Medicine 2007, 5:49 http://www.translational-medicine.com/content/5/1/49
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G2-M phase cells, and increase the accumulation of G0-G1
phase cells after treatment.
Our study revealed that the 5637 cells were the most sen-
sitive to the effect of belinostat on cell cycle distribution
and proliferation. The preferential response of this cell
line might be explained by its genetic profile, as well as the
mechanism of action that belinostat exerted on it. 5637
cells are p53 mutant, have a p16 deletion, and express p73
in IHC staining [34]. In the future, screening a patient's
tumor for these markers may give an indication of poten-
tial favorable clinical response to belinostat.
For assessment of apoptosis, both in vitro assays on all
four cell lines and in vivo caspase 3 IHC staining of mice
bladders did not show any significant difference between
the treated and un-treated groups (data not shown).
Therefore, we believe that cell cycle arrest via p21 up-reg-
ulation, not apoptosis, is the predominant mechanism of
tumor inhibition in our current system.
Gene expression analysis of belinostat-treated mice
showed increased p21WAF1 gene transcript expression. This
finding was validated by IHC analysis, where p21WAF1
expression in belinostat-treated mice was also upregu-
lated in comparison with control mice. IHC image analy-
sis of Ki67 showed a 17.8 fold increase of cell
proliferation in the control mice over that of belinostat-
treated mice. IHC image analysis of p21WAF1 expression
showed an 11.7 fold increase in the belinostat-treated
mice. Expression of the cell cycle kinase inhibitor p21 is
one of the most commonly induced genes by HDACIs
such as TSA, SAHA, and sodium butyrate [31,33,35-37].
Recent studies have shown that belinostat induces
p21WAF1  in ovarian, colon, lung, breast, prostate and
melanoma cell lines [6]. p21WAF1 is a cyclin-dependent
kinase inhibitor that is associated with activities that lead
to cell cycle arrest, and apoptosis. Belinostat also upregu-
lated metallothionine 1, another member of the HDAC
core gene family, by 4.3 fold. Metallothioneins are a
group of cysteine-rich stress response proteins that scav-
enge reactive oxygen species and heavy metals. Upregula-
tion of metallothionine 1L has also been reported by
treatment of T24 cells by three other HDACIs: SAHA, TSA,
and MS-27–275 [38], and treatment of mouse lymphosa-
rcoma cells by TSA and depsipeptide [39]. Tubulin alpha
4 was downregulated in belinostat-treated mice and con-
firmed previously reported data that tubulin is a target of
belinostat [8]. Alteration of microtubulin function is com-
monly exerted by a wide variety of chemotherapeutic
agents such as the vinca alkaloids and taxanes, two fami-
lies of agents that effectively inhibit cell division, prolifer-
ation and function. Disruption of tubulin function has
been implicated as a critical downstream event for initiat-
ing apoptosis in cancer cells [40].
Conversely, our expression profile results showed that
some genes such as histone 2, and those known to regu-
late DNA synthesis (CTP synthase) and apoptosis (clus-
terin), were oppositely regulated by belinostat compared
Table 1: Belinostat induces P21WAF1 and other HDAC core genes in transgenic mice bladders. Summary of changes in transgenic mice 
bladder gene expression for belinostat-treated versus control
Gene Name Gene Symbol Gene Function Fold Change
Acidic nuclear phosphoprotein 32 family, member B Anp32b Cell cycle 1.2
Clusterin Clu Cell death/apoptosis -2.2
Cyclin-dependent kinase inhibitor 1A P21 Cell cycle regulation 1.5
Cytidine 5'-triphosphate synthase Ctps DNA synthesis 1.8
Dehydrogenase/reductase (SDR family) member 3 Dhrs3 Short chain alchol dehydrogenase 1.3
Dehydrogenase/reductase (SDR family) member 4 Dhrs4 Short chain alchol dehydrogenase -1.4
Dehydrogenase/reductase (SDR family) member 7 Dhrs7 Short chain alchol dehydrogenase 1.3
Dehydrogenase/reductase (SDR family) member 8 Dhrs8 Short chain alchol dehydrogenase 1.5
Fucosidase, alpha-L-1, tissue Fuca1 Proteoglycan metabolism 1.6
Glutaredoxin 1 (thioltransferase) Glrx1 Glutathione dep DNA synthesis 1.3
Glutaredoxin 2 (thioltransferase) Glrx2 Glutathione dep DNA synthesis 1.2
Hepatoma-derived growth factor hdgf Transformation related protein 1.3
Hepatoma-derived growth factor hdgf Transformation related protein 2.9
Histone 2, H2be Hist2h2bb Nucelear organization -1.6
Karyopherin (Importin) beta 1 kpnb1 Nucelear translocation -1.6
Karyopherin (Importin) beta 1 kpnb1 Nucelear translocation 1.1
Karyopherin (Importin) beta 1 kpnb1 Nucelear translocation 1.4
Metalliothionine 1 Mt1 Binds heavy metals 4.3
Tubulin, alpha 2 Tuba2 Cytoskeletal structure 1.1
Tubulin, alpha 4 Tuba4 Cytoskeletal structure -1.7
Tubulin, alpha 6 Tuba6 Cytoskeletal structure -1.2
Tubulin, alpha 6 Tuba6 Cytoskeletal structure 1.2Journal of Translational Medicine 2007, 5:49 http://www.translational-medicine.com/content/5/1/49
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to other reports that used different HDACIs on bladder
and breast carcinoma cells [38]. One possible explanation
for this effect by belinostat could be due to the very nature
of HDAC inhibition. HDAC inhibition is known to dis-
rupt cell cycle function due to its alteration of chromatin
function in carcinoma cells. This undoubtedly causes
alterations in normal nuclear processes involved in cell
cycle, apoptosis, and proliferation, and subsequently
alters normal gene expression patterns. Belinostat could
affect these genes differently than other HDACIs while
still being able to induce cell cycle arrest, cell growth inhi-
bition, and p21 expression, as we have demonstrated in
our data. Our results illustrate the complexity surround-
ing the regulation of gene transcription that occurs
through chromatin remodeling by all HDACIs, including
belinostat. Most importantly, gene expression profiling in
our transgenic model showed that belinostat induced a
common set of core HDAC genes similar to those previ-
ously reported in the T24 human bladder cancer cell line
treated with different HDACIs [38].
Gene expression analysis also showed that 34 genes
involved in cell communication were significantly up or
down regulated due to belinostat treatment. HDACIs are
known to alter the expression of genes involved in cellular
communication and signal transduction [41]. One of the
most predominantly upregulated genes was secreted friz-
zled-related sequence protein 1 (SFRP1). Dysregulation of
the SFRP family in human cancers has been correlated
with the HDAC inhibitor Trichostatin A [42]. This gene
has also been shown to induce apoptosis in MCF7 breast
cancer cells [43]. We also found that belinostat induced
the dysregulation of Adiponectin (Adipoq). The altered
expression of this gene has also been shown to occur with
the HDAC inhibitor valproic acid [44].
Table 2: Belinostat induces 34 genes involved in cellular communication. Summary of fold changes in transgenic mice bladder gene 
expression for belinostat-treated versus control
Gene Name Gene Symbol Gene Function Fold Change
Adiponectin, C1Q and collagen domain containing Adipoq Cardiovascular, homeostasis 3.1
Chemokine (C-C motif) ligand 2 Ccl2 Chemotaxis, immune response 2.8
Secreted frizzled-related sequence protein 1 Sfrp1 Transmemb. receptor activity 2.5
Metallothionein 2 Mt2 Binds metal ions 1.8
Gap junction membrane channel protein alpha 1 Gja1 Intercellular channel 1.1
Protein phosphatase 2A Ppp2r2a Intrinsic catalyst activity 1
Early growth response 2 Egr2 DNA and metal ion binding 1.2
Metallothionein 1 Mt1 Metal ion binding 1.3
BMP-binding endothelial regulator Bmper Neg regulation of BMP pathway 1
RAB2 Rab2 Member Ras oncogene family 1
ADP-ribosylation factor 4 Arf4 GTP binding 1
Cell division cycle 42 homolog Cdc42 GTP binding 1
CD47 antigen CD47 Integrin-assoc. signal transducer 1
Tyrosine 3-monooxygenase activation protein Ywahz Brain signal transduction 1
Integrin beta 1 Itgb1 Fibronectin receptor beta 1.1
Integrin linked kinase Ilk ATP binding, kinase activity -1
Real guanine nucleotide dissociation stimulator-like 2 RgI2 -1.1
Regulator of G-protein signaling 19 Rgs19 Neg regulation of signal transd. -1.1
Reelin Reln Axon guidance, brain dev. -1.2
Conserved helix-loop-helix ubiquitous kinase Chuk Morphogen. of epithelial sheet -1.1
MKIAA1154 protein -1.4
Diacylglycerol kinase zeta Dgkz Protein kinase C activation -1.1
Phospholipase D2 Pld2 Catalytic activity -1.2
PTK2 protein tyrosine kinase 2 Ptk2 Angiogenesis, blood vessel dev. -1.7
5 days embryo whole body cDNA Bmp4 Bone -1.2
Deltex 2 homolog Dtx2 Notch signaling pathway -1.3
G protein-coupled receptor, family C, group 5, memb C Gprc5C Signal transduction -1.4
Disheveled, dsh homolog 1 Dvl1 Dendrite morphogenesis -1.2
Angiotensin receptor-like 1 Agtrl1 Signal transduction -1.4
RAB2B Rab2b ER to golgi and protein transprt. -1.1
Intersectin 1 Itsn1 Endocytosis, intracellular signal -1.5
Ras and Rab interactor 1 Rin1 Endocytosis, intracellular signal -1.4
Tripartite motif protein 9 Trim9 Synaptic vesicle exocytosis -2.2
Casitas B-lineage lymphoma Cbl Ca ion binding, ligase activity -4Journal of Translational Medicine 2007, 5:49 http://www.translational-medicine.com/content/5/1/49
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While the data in this report establish the link between
dose-response relationships in both in vitro and in vivo
efficacy models, it is important to note that both the in
vivo dosing schedule and in vitro concentration ranges
chosen for these experiments are achievable in patients. In
the current clinical setting, belinostat is dosed at the MTD
(1000 mg/m2) given intravenously, which results in a
Cmax of ~100 µM and AUC0-t of ~31 µM*hr/mL (unpub-
lished data), treatments are given 5 times per week in a 3
week cycle. Exposure of cells in culture to belinostat con-
centrations of 1–5 µM over 48 hr in this study is well
within the clinical range and this resulted in significant
cell growth inhibition and cell cycle arrest. In accordance
with the clinical trial, in this study, belinostat, adminis-
tered in transgenic mice five times per week, showed effi-
cacy at a dose in the lower range of clinical dosing, 100
mg/kg, human equivalent dose of 300 mg/m2. Hence,
both in vitro and in vivo dosing of belinostat used in this
study are within clinically achievable dosing regimens.
Our Ha-ras transgenic model of human bladder cancer
offered a unique correlation to the onset and progression
of human superficial bladder cancer not available in the
xenograft system. In these mice, superficial tumors occu-
pied the entire bladder volume at the endpoint of this
study making miscrodissection impractical. Since micro-
dissection could not be performed we weighed the entire
bladder from each animal and used it as a surrogate
marker to assess tumor burden. However, when all mice
were sacrificed and underwent pathological dissection
and analysis, all bladder tumors in the belinostat-treated
mice were smaller and occupied less space of the total
bladder capacity than untreated mice. Belinostat-treated
mice had a lower incidence of bladder tumors compared
to untreated mice based on total bladder weight. This
indicates that belinostat was able to decrease the progres-
sion of existing established superficial bladder cancer. Of
note, the Ha-ras mice used in this study all have low-grade
superficial bladder tumors starting at 3 months that
progress to occupy the entire bladder and force the mice
to succumb to obstructive neuropathy at 6–7 months of
age. Although the mice in this study were not allowed to
succumb to obstructive neuropathy, we anticipate that
untreated mice would succumb to obstructive neuropathy
quicker than those mice treated with belinostat based on
the former's increased endpoint tumor burden. Another
alternative to microdissection would be the use of the
novel computed tomography system developed to image
the urinary tract and tumors in live mice [45]. This tech-
nique may offer potential to quantitatively assess tumor
size in superficial transgenic mice in future experiments.
Previous phase I trials of the histone deacetylase inhibi-
tors phenylbutyrate [9] and depsipeptide [10] have shown
minimal toxicity to patients. A recent phase 1 trial of MS-
275, a benzamide derivative with potent HDAC inhibi-
tion and antitumor activity in preclinical models, was
used in patients with advanced myeloid leukemias and
showed no response by classical criteria, but suggested a
potentially better clinical outcome if tested in a cohort of
patients with less-advanced disease [46]. A phase 2 trial
using vorinostat in combination with carboplatin and
paclitaxel showed that both dose schedules used were well
tolerated, and the study had encouraging anticancer activ-
ity in patients with previously untreated non-small cell
lung cancer [47].
When used in combination with established chemothera-
peutics such as carboplatin and docetaxel, belinostat was
found to synergistically inhibit both in vitro and in vivo
ovarian cancer cell growth [8]. Belinostat has also been
shown to synergize with 5-fluorouracil to inhibit colon
cancer cell growth in vitro and in vivo, and demonstrated
a strong rationale for the use of belinostat and 5-fluorou-
racil in combination in the clinic [5]. Currently, belinostat
is undergoing investigation for a wide range of solid and
hematologic malignancies either as a single-agent, or in
combination with other active anti-cancer agents, includ-
ing 5-FU, carboplatin, paclitaxel, cis-retinoic acid, azaciti-
dine and Velcade (bortezomib) for Injection. Promising
results include good tolerance and a broad range of anti-
tumor activity. Intravenous belinostat is currently being
evaluated in multiple clinical trials as a potential treat-
ment for multiple myeloma, T- and B-cell lymphomas,
AML, mesothelioma, liver, colorectal, ovarian cancers,
either alone or in combination with anti-cancer therapies.
An oral formulation of belinostat is also being evaluated
in a Phase I clinical trial for patients with advanced solid
tumors. Given the well tolerability of belinostat, these
results indicate that further investigation of belinostat as a
bladder cancer treatment, either used alone or in combi-
nation with other chemotherapeutics, is well warranted.
Conclusion
In this study, we showed that belinostat induced growth
inhibition and cell cycle arrest in a panel of human TCC
urinary bladder cells in vitro at low micromolar concen-
trations. Belinostat increased gene and IHC expression of
p21WAF1 at both mRNA and protein levels, and treatment
with belinostat decreased cell growth and proliferation in
our transgenic mouse model of superficial bladder cancer
at a concentration that was without apparent toxicity to
the mice. Taken together, these findings suggest that
belinostat is a potent and relatively tolerable agent for the
treatment of superficial urinary bladder cancer.
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